Breaking News
Investing Pro 0
NEW! Get Actionable Insights with InvestingPro+ Try 7 Days Free

Pfizer leaves COVID product forecast unchanged, shares fall

Coronavirus Jul 28, 2022 17:20
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
2/2 © Reuters. FILE PHOTO: Vials of the Pfizer-BioNTech Comirnaty coronavirus disease (COVID-19) vaccine are pictured in a General practitioners practice in Berlin, Germany, April 10, 2021. REUTERS/Fabrizio Bensch/File Photo 2/2
 
PFE
-1.10%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
PFIZ34
+1.07%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Manas Mishra and Michael Erman

(Reuters) -Pfizer Inc did not raise its 2022 forecast for sales of its COVID-19 vaccine and antiviral treatment on Thursday, and its shares fell nearly 5% before recovering.

The U.S. drugmaker maintained its full-year forecast of around $54 billion for its COVID products, even as second-quarter sales of its Paxlovid antiviral pills were much higher-than-expected, raising concerns among some analysts over Pfizer (NYSE:PFE)'s long-term growth prospects.

Paxlovid sales of $8.1 billion topped Wall Street estimates by more than $1 billion, as a surge in cases drove demand. U.S. President Joe Biden took a course of the drug for his recent bout with COVID.

The company also kept its overall sales forecast of between $98 billion to $102 billion unchanged, citing the impact of a strong dollar.

Pfizer has enjoyed an unprecedented rise in sales since the COVID-19 vaccine it developed with BioNTech rolled out globally. But sales have started to slow since last year.

Wall Street analysts are divided over the durability of both the vaccine and Paxlovid, as pandemic urgency wanes.

JP Morgan analyst Chris Schott in a research note said the long-term sustainability of Pfizer's COVID-19 business is up for debate, and that the company's ability to generate new drugs from its pipeline will be increasingly important for it to outperform expectations.

Pfizer has been banking on sales of vaccine booster doses, including an Omicron-tailored version expected in the fall, to drive demand in the next few years.

Pfizer and BioNTech last month signed a $3.2 billion deal with the U.S. government for 105 million doses of their vaccine, which includes supply of a retooled Omicron-adapted booster, pending regulatory clearance.

Overall sales of $27.74 billion for the quarter exceeded analysts' estimates of $25.74 billion.

Citi analyst Andrew Baum said the picture excluding the COVID business was less rosy, as sales of important products such as breast cancer drug Ibrance and arthritis treatment Xeljanz came in well below Wall Street estimates at $1.32 billion and $430 million, respectively.

COVID-19 vaccine sales rose 13% to $8.85 billion.

Pfizer's second-quarter profit rose to $9.91 billion from $5.56 billion a year ago. Excluding items, it earned $2.04 per share, topping analysts' estimates by 26 cents.

Pfizer shares were down 1.2% at $50.93.

Pfizer leaves COVID product forecast unchanged, shares fall
 

Related Articles

Denmark to allow mink breeding again from 2023
Denmark to allow mink breeding again from 2023 By Reuters - Sep 23, 2022

COPENHAGEN (Reuters) -Denmark will not extend a ban on mink breeding when the current ban expires at the turn of the year, the country's agriculture ministry said on Friday. The...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email